Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)

Clin Neuropharmacol. 2004 Mar-Apr;27(2):58-62. doi: 10.1097/00002826-200403000-00003.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / adverse effects*
  • Antiparkinson Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Dyskinesia, Drug-Induced / drug therapy*
  • Dyskinesia, Drug-Induced / etiology
  • Female
  • Humans
  • Levodopa / adverse effects*
  • Male
  • Medical Records
  • Organic Chemicals
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Organic Chemicals
  • Levodopa
  • sarizotan